SCHEMBL2837665

SCHEMBL2837665

CCCCCOc1ccccc1N1C(=O)C=CC1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 9/20 0.58
TLR9 Q9NR96 1/20 0.48
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
NR1I2 O75469 1/20 0.47
LMNA P02545 1/20 0.47
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
ADRA2A P08913 1/20 0.47
OPRK1 P41145 1/20 0.47
HTR2B P41595 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3691135 0.83 MGLL (0.66) MGLLTLR9MAPTFAAHALDH1A1
SCHEMBL29065798 0.80 MGLL (0.65) MGLLTLR9SMN1; SMN2FAAHALDH1A1
SCHEMBL28379749 0.78 CNR1 (0.47) MGLLTLR9MEN1LMNAKMT2A
SCHEMBL1704226 0.77 MGLL (0.53) MGLLTLR9FAAH
SCHEMBL6651604 0.75 CYP1A2 (0.63) MAPTMEN1NR1I2LMNACHRM2
SCHEMBL30096940 0.75 CYP1A2 (0.63) MAPTMEN1NR1I2LMNACHRM2
SCHEMBL9838856 0.75 MEN1 (0.46) MGLLTLR9MAPTMEN1LMNA
SCHEMBL29439366 0.74 MGLL (1.00) MGLLTLR9MAPTMEN1KMT2A
SCHEMBL141734 0.74 MGLL (1.00) MGLLTLR9MAPTMEN1KMT2A
SCHEMBL3879458 0.74 MGLL (0.71) MGLLTLR9FAAHALDH1A1ALDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130299747-A1 CURATIVES FOR EPOXY COMPOSITIONSERS DESIGNER MOLECULES, INC. 2013-11-14 US disclosed
US-20130199724-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-08-08 US disclosed
US-8431655-B2 Curatives for epoxy compositions DESIGNER MOLECULES, INC. (US) 2013-04-30 US disclosed
US-20100249276-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-09-30 US disclosed
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-05-06 US disclosed
WO-2008124797-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249276-A1 CURATIVES FOR EPOXY COMPOSITIONS ALOX5, LTC4S, ALOX15B MGLL 3323/4885TLR9 3209/4885MAPT 3557/4885
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS ALOX5, LTC4S, ALOX15B MGLL 3533/4885TLR9 3197/4885MAPT 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.